Health Care • Biotechnology: Biological Products (No Diagnostic Substances)
$170.68 ▲ +5.07
(+3.06%)
MKT CAP: $205.35B • VOL: 11.43M
52W L $117 52W H $176
GILD // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $29.44B | $28.75B | $27.12B |
| YoY Revenue Growth % | +2.4% | +6.0% | — |
| Gross Profit | $23.21B | $22.50B | — |
| Gross Margin % | 78.8% | 78.3% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | $10.02B | $1.66B | $7.61B |
| Operating Margin % | 34.0% | 5.8% | 28.0% |
| Net Income (GAAP) | $8.51B | $480.0M | $5.67B |
| EBITDA (Normalized) | $10.47B | $2.08B | $8.58B |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | $10.02B | $10.83B | $8.01B |
| Capital Expenditures (CapEx) | $563.0M | $523.0M | $1.22B |
| Free Cash Flow (FCF) | $9.46B | $10.30B | $6.79B |
| FCF Margin % | 32.1% | 35.8% | 25.0% |
| Return on Invested Capital (ROIC %) | 20.7% | 3.5% | 8.8% |
| Cash & Short-Term Equivalents | — | — | — |
| Total Debt (Short + Long Term) | $22.13B | $24.90B | $26.43B |
| Total Stockholders' Equity | $22.70B | $19.33B | $54.21B |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR GILD.